A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer

发表于 2026-8-17 09:13:44

期刊：Cancer Immunology Research

文献作者：Brandon M. Huffman; Osama E. Rahma; Kevin Tyan; Yvonne Y. Li; Anita Giobbie-Hurder; Benjamin L. Schlechter; Bruno Bockorny; Michael P. Manos; Andrew D. Cherniack; Joanna Baginska; Adrián Marino-Enríquez; Katrina Z. Kao; Anna K. Maloney; Allison Ferro; Sarah Kelland; Kimmie Ng; Harshabad Singh; Emma L. Welsh; Kathleen L. Pfaff; Marios Giannakis; Scott J. Rodig; F. Stephen Hodi; James M. Cleary

出版日期：2025-1-9

DOI号：10.1158/2326-6066.cir-23-1027

下载链接：https://aacrjournals.org/canceri ... 633/cir-23-1027.pdf

文献链接：https://doi.org/10.1158/2326-6066.cir-23-1027

当前文献来源于 American Association for Cancer Research (AACR)。

备注信息：

发表于 2026-8-17 09:13:45

: 当前求助已完成，请重新发起求助。
已完结状态的附件将会在24小时内删除。

[AACR] A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer

已采纳

同分类求助

最新回复

站点公告

今日热心研友

（热心研友QQ群）

[AACR] A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer 一键复制

已采纳